|
 |
| home > ebr > autumn 2003 > medicinal cannabis production - the botanist's view |
|
|
 PUBLICATIONS |
European BioPharmaceutical Review
|
| Cannabis has been used for medicinal purposes for thousands of years in Asian and Middle Eastern countries. The medicinal use of cannabis in Europe and North America has declined during the 20th Century largely due to the lack of standardised preparations (1). The tide has turned. In the near future Britain should become the first country to license a cannabis-based pharmaceutical (2). The principal active ingredients responsible for the efficacy of cannabis are phytocannabinoids, a family of over sixty 21-carbon terpenophenolic compounds that are unique to cannabis. Sativex®, the first UK cannabis-based medicine contains two from this family - Tetrahydrocannabinol (THC) and Cannabidiol (CBD). THC is the principal psychoactive ingredient in recreational cannabis. CBD is not psychoactive but both cannabinoids have profound medicinal properties. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Paediatric Clinical Trials
19-20 January 2009, Copthorne Tara Hotel, London, UK
More info >>
|
|
 |
News and Press Releases |
 |
Stora Enso with DDSi is Winner of HCPC-Europe Packaging Award 2008
11th November 2008
More info >> |
|
 |
